Clinical & translational oncology

• 

  Año 2026, Vol. 28, Número 4

  • REVIEW ARTICLE

    • Epidrugs in cancer: mechanisms, applications, and future direction

      Roshni Bibi, Lakshmi Varshetha, Rakshit Kamal Lahary, Jahnavi Namburi, Fardeen Ahmed Laskar, Koustav Sarkar

      • Resumen

      págs. 1085-1100

      

    • RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update

      Sandeep Appunni, Vivek Anand, Madhuram Khandelwal, Nidhi Gupta, Muni Rubens, Alpana Sharma

      • Resumen

      págs. 1101-1118

      

    • Beyond the infusion: nursing at the vanguard of cytokine release syndrome rescue in CAR-T cell therapy

      Ruihong Zuo, Meijie Han

      • Resumen

      págs. 1119-1137

      

  • CLINICAL GUIDES IN ONCOLOGY

    • SEOM–GEMCAD–TTD clinical guidelines for anal cancer (2025)

      Mónica Maria Guillot Morales, Ana Fernández Montes, Julen Fernández Plana, Ismael Ghanem Cañete, Mireia Gil Raga, Jerónimo Jiménez Castro, Ignacio Juez Martel, Joan Maurel Santasusana, Eduardo Polo Marqués, M. A. Gómez España

      • Resumen

      págs. 1138-1150

      

    • SEOM–TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)

      Antonio Rueda Domínguez, Beatriz Cirauqui Cirauqui, Almudena García Castaño, Ruth Álvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fernández, Leticia Iglesias Rey, J. Rubió Casadevall, Virginia Arrazubi Arrula, Ricard Mesía Nin

      • Resumen

      págs. 1151-1164

      

  • RESEARCH ARTICLE

    • Targeting the NF-κB pathway represents a potential strategy to attenuate HGF-induced resistance to KRAS G12C inhibitors in lung adenocarcinoma

      Demin Jiao, Yu Chen, Xiang Liu, Wei Xu, Xiali Tang, Jun Chen, Qingyong Chen

      • Resumen

      págs. 1165-1177

      

    • Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma

      Minghe Lv, Lei Tang, Liu Yang, Jingping Yu, Qing Ji, Ruping Zhao

      • Resumen

      págs. 1178-1197

      

    • Prognostic significance of liver-to-muscle FDG uptake ratio and ınflammatory biomarkers in small cell lung cancer

      Kadriye Başkurt, Semra Demirtaş Şenlik, Galip Can Uyar, Enes Yeşilbaş, Omur Berna Cakmak Oksuzoglu, Osman Sütcüoğlu

      • Resumen

      págs. 1198-1210

      

    • LncRNA FEZF1-AS1 promotes the tumorigenesis and suppresses ferroptosis in non-small cell lung cancer through the TNF-α/NF-κB pathway

      WenRui Hou, DianMing Li, JingXin Wang, WeiQi Yin

      • Resumen

      págs. 1211-1222

      

    • Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study

      Wenhao Zhao, Min Yu, Youling Gong, Meijuan Huang, Jianxin Xue

      • Resumen

      págs. 1223-1233

      

    • Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study

      Şefika Arzu Ergen, Fazilet Öner Dinçbaş, Evrim Metcalfe, Şule Karabulut Gül, Serap Akyürek, Güler Yavaş, Beyza Şirin Özdemir, Birsen Yücel, Ayşe Altınok, Banu Atalar, Pelin Altınok, Melek Yakar, Hüseyin Tepetam, Sümerya Duru Birgi, Cagdas Yavas, Aylin Fidan Korcum, Ali Murat Tatlı, Fulden Yumuk

      • Resumen

      págs. 1234-1245

      

    • Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial

      Yuting Cui, Qiuxia Wu, Yue Hao, Guannan Wu, Qinpei Cheng, Xincui Song, Lu Chen, Xin Hua, Yuxin Jiang, Di Cheng, Suhua Zhu, Xin Liu, Yong Song, Tangfeng Lv, Ping Zhan

      • Resumen

      págs. 1246-1256

      

    • Adjuvant immune checkpoint inhibitors in early-stage non-small cell lung cancer: insights from a systematic review and meta-analysis

      Isadora Mamede, Carlos Stecca, Gabriela Gazzoni, Ana Caroline Fonseca Alves, Fernanda Ronchi, Vinicius Ernani

      • Resumen

      págs. 1257-1266

      

    • Real-world survival outcomes with first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancer

      Emmanouil Panagiotou, Ioannis Athanasios Vathiotis, Austin Montgomery, Camille Moeckel, Mirsini Livanou, Michail Mastrogeorgiou, Athanasios Trimis, Ioannis Trontzas, Nikolaos Konstantinos Syrigos, Ioannis Mouratidis, Georgios Evangelou, Ilias Georgakopoulos Soares, Konstantinos Nikolaos Syrigos

      • Resumen

      págs. 1267-1276

      

    • CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy

      Salih Karatlı, Özgen Ahmet Yıldırım

      • Resumen

      págs. 1277-1284

      

    • Loss of miR-122 promotes cell migration and poor prognosis in triple-negative breast cancer treated by neoadjuvant chemotherapy

      Mauricio Flores Fortis, Isidro X. Pérez Añorve, Carlos C. Patiño Morales, Ernesto Soto Reyes, Claudia H. González De la Rosa, Joaquín Manzo Merino, Arturo Aguilar Rojas, Nicolas Villegas, Elena Arechaga Ocampo

      • Resumen

      págs. 1285-1302

      

    • Patterns of practice for breast cancer post-operative radiation therapy in Italy according to the ESTRO-ACROP consensus and AIRO position paper: a national survey on the behalf of the Italian association of radiotherapy and clinical oncology (AIRO)

      Samantha Dicuonzo, Carlotta Becherini, Simona Borghesi, Francesca Cucciarelli, Alba Fiorentino, Ruggero Spoto, Edy Ippolito, Elisabetta Perrucci, Barbara A. Jereczek-Fossa, Maria Cristina Leonardi, Icro Meattini, Cynthia Aristei, Isabella Palumbo

      • Resumen

      págs. 1303-1313

      

    • Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon

      Marta Solange Camarinha Ramos Costa, Ana Caroline Alves da Costa, Esdras Edgar Batista Pereira, Diana Feio da Veiga Borges Leal, Antônio André Conde Modesto, Elisa da Silva Menezes, Rita de Cássia Calderaro Coelho, Sidney Emanuel Batista dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos

      • Resumen

      págs. 1314-1323

      

    • Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis

      Nayara Rozalem Moretti, Hideki Zimermann Kamitani, Pedro Henrique de Souza Wagner, Gustavo Tadeu Freitas Uchôa Matheus, Barbara Antonia Dups Talah, Larissa Emi Tanimoto, Isabella Caroline de Oliveira Barretto, Francisco Cezar Aquino de Moraes

      • Resumen

      págs. 1324-1339

      

    • Unmasking hidden trends: subsite-specific mortality patterns in colorectal and anal cancers in Spain, 1999–2023

      Lucía Cayuela Rodríguez, Victoria Achaval, Gema Flox Benitéz, Aurelio Cayuela Domínguez

      • Resumen

      págs. 1340-1347

      

    • Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis

      Atta Ullah Khan, Yasameen Hameed Jasim, Kanza Shahid, Jasur Saidov, Zamira Atamuratova, Dilbar Urazbaeva

      • Resumen

      págs. 1348-1362

      

    • Integrated sleep and psychological interventions enhance postoperative recovery and quality of life in colorectal cancer: a randomized controlled trial

      Gang Wang, Shengjie Pan

      • Resumen

      págs. 1363-1373

      

    • Epidemiological patterns, temporal trends in management and long-term outcomes in testicular cancer: a 30-year single center experience

      Patricia Capdevila, Jorge Aparicio Urtasun

      • Resumen

      págs. 1374-1383

      

    • Management of high-risk prostate cancer in Spain: results from a national patterns of care survey

      Víctor Duque Santana, María Antonia Gómez Aparicio, Abrahams Ocanto, Elías Gomis Sellés, Miren Gaztañaga Boronat, Patricia Willisch Santamaría, Javier Maldonado Pijoan, Manuel Luis Blanco Villar, I. Henríquez, Pedro Lara Jiménez, Ivone Ribeiro, Alai Goñi Ramírez, Marta López Valcárcel, Ignacio Visus, Susana Pérez Echagüen, Pilar Alonso Martínez, Victoria Vera Barragán, Carmen Velilla Millán, Ana Illescas Vacas, Pilar Samper Ots, Luis Alberto Glaría Enríquez, Angel Montero, Laura Montezuma, Rocío del Castillo Acuña, URONCOR investigators

      • Resumen

      págs. 1384-1393

      

    • CHI3L1 is a diagnostic biomarker involved in immune infiltration of gastric cancer

      Yan Yongkang, Li Wei, Liu Huifang, Zhao Hui, Li Jing, Wang Tongtong, Tian Zhiwei, Yang Jie

      • Resumen

      págs. 1394-1410

      

    • Are conventional and hypofractionated chemoradiotherapy comparable in glioblastoma patients?

      Fiorella Cristina Di Guglielmo, Ilaria Bonaparte, Valerio Davì, Pietro Guida, Maria Paola Ciliberti, Fabiana Gregucci, Alessia Surgo, Morena Caliandro, Roberta Carbonara, David Giraldi, Vincenzo Fanelli, Giammarco Surico, Maria Annunziata Gentile, Roberto Calbi, Valeria Internò, Letizia Laera, Tiziana Talienti, Francesco Signorelli, Giuseppe Lombardi, Alba Fiorentino

      • Resumen

      págs. 1411-1421

      

    • Adjuvant nivolumab vs pembrolizumab in stage IIB/IIC melanoma: a reinforcement learning-based simulation study

      Perihan Perkin, Fahriye Tuğba Köş

      • Resumen

      págs. 1422-1430

      

    • The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients

      Apoorva Reddy, John M. Hampton, Susan J. Park, Faith Dickerson, Betty Chewning, Natalie Schmitz, Kristine Kwekkeboom, Heather Neuman, Amy Trentham-Dietz

      • Resumen

      págs. 1431-1443

      

    • Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis

      Irene González Caraballo, Bárbara Lobato Delgado, Magdalena Carmen Ruiz Zamorano, Mercedes Salgado Fernández, Vanesa Pachón Olmos, Joaquina Martínez Galán, Victoria Eugenia Castellón Rubio, Itziar Gardeazabal, Ana Ferrer, Jaime Rubio Pérez, Ignacio García Escobar, Isaura Fernández Pérez, Teresa Quintanar, Carme Font Puig, Javier Soto Alsar, Laura Ortega Morán, José Manuel Soria, Andrés Jesús Muñoz Martín

      • Resumen

      págs. 1444-1450

      

    • Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis

      Mathieu Faigner, Lucie Karayan Tapon, Ulrich Cortes, Birama Ndiaye, Marine Martel, Pierre Rivet, Jade Duche, Nicolas Isambert, David Tougeron, Camille Evrard

      • Resumen

      págs. 1451-1459